alexa
Reach Us +44-1625-708989
A One-Stop Novel Drug for Malaria Treatment and Control | OMICS International | Abstract

Journal of Infectious Disease and Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

A One-Stop Novel Drug for Malaria Treatment and Control

Manoswini Dash and Aparup Das*

Evolutionary Genomics and Bioinformatics Laboratory, National Institute of Malaria Research, Dwaraka, New Delhi, India

*Corresponding Author:
Aparup Das
Evolutionary Genomics and Bioinformatics Laboratory
Division of Genomics and Bioinformatics
National Institute of Malaria Research
Dwarka, New Delhi, India
Tel: +91 011 25307 322
Fax: +91 11 25307377
E-mail: [email protected]

Received date: February 11, 2016; Accepted date: February 22, 2016; Published date: February 27, 2016

Citation: Das A and Dash M (2016) A One-Stop Novel Drug for Malaria Treatment and Control. J Emerg Infect Dis 1:107. doi:10.4172/2472-4998.1000107

Copyright: © 2016 Dash M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Like many tropical diseases, malaria poses great threat to mankind in the under developed and developing countries. Control of malaria majorly depends on early diagnosis and thereafter effective treatment by antimalarials. However, malaria treatment is severely hampered by evolution and spread of drug-resistant malaria parasites, including the currently used drug artemisinin. Malaria control programs therefore need an antimalarial that can not only promptly kill the parasites with minimal side effect to humans, but also is affordable by the community and the chance of evolution of resistance is minimal. A wonder drug (named DDD107498) that can bear all the above properties has recently been developed and about to enter human clinical trial. Among other properties, (i) Effect on multiple species of malaria parasites at several life cycle stages (ii) Single dose effectiveness, (iii) Good pharmacokinetic properties and (iv) Low risk of parasite transmission due to active gametocyte clearance make the compound a perfect new-generation antimalarial.

Keywords

Top